JP2018502083A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502083A5
JP2018502083A5 JP2017533635A JP2017533635A JP2018502083A5 JP 2018502083 A5 JP2018502083 A5 JP 2018502083A5 JP 2017533635 A JP2017533635 A JP 2017533635A JP 2017533635 A JP2017533635 A JP 2017533635A JP 2018502083 A5 JP2018502083 A5 JP 2018502083A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
fluoroalkyl
deuteroalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502083A (ja
JP6764866B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/012909 external-priority patent/WO2016115054A2/en
Publication of JP2018502083A publication Critical patent/JP2018502083A/ja
Publication of JP2018502083A5 publication Critical patent/JP2018502083A5/ja
Application granted granted Critical
Publication of JP6764866B2 publication Critical patent/JP6764866B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533635A 2015-01-13 2016-01-11 Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用 Expired - Fee Related JP6764866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103033P 2015-01-13 2015-01-13
US62/103,033 2015-01-13
PCT/US2016/012909 WO2016115054A2 (en) 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Publications (3)

Publication Number Publication Date
JP2018502083A JP2018502083A (ja) 2018-01-25
JP2018502083A5 true JP2018502083A5 (cg-RX-API-DMAC7.html) 2019-02-14
JP6764866B2 JP6764866B2 (ja) 2020-10-07

Family

ID=56406559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533635A Expired - Fee Related JP6764866B2 (ja) 2015-01-13 2016-01-11 Ca2+放出活性化Ca2+(CRAC)チャネルのモジュレーターおよびその薬学的使用

Country Status (9)

Country Link
US (1) US10213412B2 (cg-RX-API-DMAC7.html)
EP (1) EP3245189B1 (cg-RX-API-DMAC7.html)
JP (1) JP6764866B2 (cg-RX-API-DMAC7.html)
CN (1) CN107207431B (cg-RX-API-DMAC7.html)
AU (1) AU2016207014B2 (cg-RX-API-DMAC7.html)
CA (1) CA2969814C (cg-RX-API-DMAC7.html)
ES (1) ES2825798T3 (cg-RX-API-DMAC7.html)
MX (1) MX379440B (cg-RX-API-DMAC7.html)
WO (1) WO2016115054A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207014B2 (en) 2015-01-13 2020-07-16 Vivreon Biosciences, Llc Modulators of CA2+ release-activated CA2+ (CRAC) channels and pharmaceutical uses thereof
AU2018353533A1 (en) * 2017-10-17 2020-05-28 Rhizen Pharmaceuticals Sa CRAC channel modulators for treating esophageal cancer
US20200281918A1 (en) * 2017-10-30 2020-09-10 Rhizen Pharmaceuticals Sa Calcium release-activated calcium channel modulators for treating hematological and solid cancers
EA202190556A1 (ru) 2018-09-14 2021-08-24 Ризен Фармасьютикалс А Г Композиции, содержащие ингибитор crac и кортикостероид, и способы их применения
KR20220154165A (ko) * 2020-03-16 2022-11-21 조마젠 바이오사이언시즈 엘티디 Nlrp3 조절제
CA3179405A1 (en) * 2020-05-20 2021-11-25 Kenneth A. Stauderman Methods and compositions for treating acute kidney injury

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644009A (en) * 1984-10-29 1987-02-17 Usv Pharmaceutical Corporation Aryl-alkyl heterocyclic compounds
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
BR9306040A (pt) * 1992-03-06 1997-11-18 Statens Seruminstitut Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
JP3143571B2 (ja) * 1994-01-19 2001-03-07 三共株式会社 ピロロピリダジン誘導体
CN1044811C (zh) * 1994-01-19 1999-08-25 三共株式会社 吡咯并哒嗪衍生物
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
CA2580852A1 (en) * 2004-09-21 2006-03-30 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
BRPI0611631A2 (pt) * 2005-06-24 2010-09-21 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
TW201130488A (en) * 2010-02-03 2011-09-16 Daiichi Sankyo Co Ltd Pyrrole compound
ES2602140T3 (es) * 2011-06-27 2017-02-17 Newron Pharmaceuticals S.P.A. Derivados de arilalquilaminocarboxamida fluorados
CA2913987A1 (en) * 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
AU2016207014B2 (en) 2015-01-13 2020-07-16 Vivreon Biosciences, Llc Modulators of CA2+ release-activated CA2+ (CRAC) channels and pharmaceutical uses thereof

Similar Documents

Publication Publication Date Title
JP2018502083A5 (cg-RX-API-DMAC7.html)
JP2019163290A5 (cg-RX-API-DMAC7.html)
JP2010519206A5 (cg-RX-API-DMAC7.html)
JP2010509342A5 (cg-RX-API-DMAC7.html)
HRP20171610T1 (hr) Selektivni inhibitori pi3k delta
HRP20211151T1 (hr) Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama
JP2017501234A5 (cg-RX-API-DMAC7.html)
JP2012504604A5 (cg-RX-API-DMAC7.html)
JP2019519598A5 (cg-RX-API-DMAC7.html)
JP2019515043A5 (cg-RX-API-DMAC7.html)
JP2011016800A5 (cg-RX-API-DMAC7.html)
JP2013525433A5 (cg-RX-API-DMAC7.html)
JP2017516785A5 (cg-RX-API-DMAC7.html)
JP2019518071A5 (cg-RX-API-DMAC7.html)
JP2019034943A5 (cg-RX-API-DMAC7.html)
CA2669695A1 (en) Tetrahydropyridinyl compounds for inflammation and immune-related uses
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP2010535218A5 (cg-RX-API-DMAC7.html)
JP2012532112A5 (cg-RX-API-DMAC7.html)
JP2009534407A5 (cg-RX-API-DMAC7.html)
JP2013536259A5 (cg-RX-API-DMAC7.html)
JP2017538773A5 (cg-RX-API-DMAC7.html)
CA2704724A1 (en) 5use of a peptide as a therapeutic agent
JP2019515952A5 (cg-RX-API-DMAC7.html)
JP2003531103A5 (cg-RX-API-DMAC7.html)